EHA 2016: Side effects of panobinostat in multiple myeloma

EHA 2016: Side effects of panobinostat in multiple myeloma

VJHemOnc

4 years
439 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Andrew Spencer, MD, PhD from the Monash University, Melbourne, Australia discusses the side effects of panobinostat in multiple myeloma (MM). Most patients did not tolerate the initial dose 45 mg/m2 but with a dose reduction to 30 mg/m2 or 20 mg/m2, most patients tolerated the drug well for the six month duration. The main side effects were gastrointestinal (GI) related and included diarrhoea. There was no relevant myeloid suppression and fatigue was not observed. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Up Next Autoplay